Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors Recruiting

2023-507141-28-00 Solid tumor 2025-01-29
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Recruiting

2024-512264-66-00 Solid Tumors 2025-01-29
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting

2024-519790-19-00 Relapsed/refractory large B-cell non-Hodgkin lymphoma, 2025-01-24
CHOPIN Recruiting

2024-516127-14-01 metastasized melonama uveal 2025-01-21
A Phase 1/2 Study of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 Recruiting

2023-506028-10-00 Myotonic Dystrophy 2024-12-11
An open-label, non-randomised safety and tolerability Proof of Concept Trial to examine multiple dosing addition of glycocholate (GC) and bu… Recruiting

2024-511124-14-00 Postoperative obesity 2024-12-10
A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting

2023-509230-19-00 Advance solid tumors 2024-11-14
A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe… Recruiting

2023-508517-16-00 Advanced Solid Tumors with a KRAS p.G12C Mutation 2024-11-10
New adjuvant vaccine in glioblastoma, a Phase 1/2a study (NAVIG-1) Recruiting

2024-514567-26-00 glioblastoma 2024-11-08
Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO) Recruiting

2023-508254-26-00 Primary aldosteronism 2024-11-06
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting

2023-505334-10-01 Unresectable, Locally Advanced, or Metastatic Solid Tum 2024-10-30
Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF… Recruiting

2024-511858-44-00 Inclusion Body Myositis 2024-10-24
Repairing Peri-Anal Fistulas with regenerative cell therapeutics (REP-PAF) Recruiting

2022-502659-73-01 Crypto-glandular perianal fistula 2024-10-09
BORTEM 17 Recruiting

2024-515142-16-00 Grade IV recurrent glioma which includes both glioblast 2024-10-03
A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu… Recruiting

2023-510203-21-00 locally advanced or metastatic non-small cell lung canc 2024-09-24
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, pha… Recruiting

2022-501910-79-01 Ovarian cancer 2024-09-18
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients with An… Recruiting

2024-512589-32-00 Angelman syndrome 2024-09-16
A Phase I/II Study of AZD5863 in Adult Participants with Advanced or Metastatic Solid Tumors Recruiting

2023-504139-42-00 Advanced or metastatic solid tumors 2024-09-06
A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy… Recruiting

2024-511074-80-01 Platinum-resistant high-grade ovarian cancer (PROC) or 2024-09-06
Long-term safety bucket trial with NVDX3, an osteogenic implant of human allogenic origin Recruiting

2024-511661-11-01 Distal Radius fracture 2024-08-22
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas Recruiting

2023-503550-13-00 Large Granular Lymphocytic Leukemia or Cytotoxic Lympho 2024-08-08
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML. Recruiting

2023-505806-41-00 Acute myeloid leukemia 2024-08-01
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with ad… Recruiting

2023-504199-19-00 Solid Tumours 2024-06-26
Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting

2023-508139-29-00 Advanced or metastatic solid tumors 2024-06-26